IL166068A0 - Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea - Google Patents
Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoeaInfo
- Publication number
- IL166068A0 IL166068A0 IL16606804A IL16606804A IL166068A0 IL 166068 A0 IL166068 A0 IL 166068A0 IL 16606804 A IL16606804 A IL 16606804A IL 16606804 A IL16606804 A IL 16606804A IL 166068 A0 IL166068 A0 IL 166068A0
- Authority
- IL
- Israel
- Prior art keywords
- diarrhoea
- treatment
- combination
- metal salt
- ibat inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0216321.0A GB0216321D0 (en) | 2002-07-13 | 2002-07-13 | Therapeutic treatment |
| PCT/GB2003/002978 WO2004006899A1 (en) | 2002-07-13 | 2003-07-09 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166068A0 true IL166068A0 (en) | 2006-01-15 |
Family
ID=9940407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16606804A IL166068A0 (en) | 2002-07-13 | 2004-12-30 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060083790A1 (xx) |
| EP (1) | EP1539120A1 (xx) |
| JP (1) | JP2005536502A (xx) |
| KR (1) | KR20050027108A (xx) |
| CN (1) | CN1668286A (xx) |
| AR (1) | AR040553A1 (xx) |
| AU (1) | AU2003246932A1 (xx) |
| BR (1) | BR0312427A (xx) |
| CA (1) | CA2492374A1 (xx) |
| GB (1) | GB0216321D0 (xx) |
| IL (1) | IL166068A0 (xx) |
| IS (1) | IS7678A (xx) |
| MX (1) | MXPA05000461A (xx) |
| NO (1) | NO20045527L (xx) |
| PL (1) | PL374665A1 (xx) |
| RU (1) | RU2004138083A (xx) |
| TW (1) | TW200418821A (xx) |
| UY (1) | UY27890A1 (xx) |
| WO (1) | WO2004006899A1 (xx) |
| ZA (1) | ZA200500212B (xx) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| WO2008108735A1 (en) | 2007-03-08 | 2008-09-12 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| DK2637668T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
| SG190433A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
| US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| JP6751020B2 (ja) | 2014-06-25 | 2020-09-02 | Ｅａファーマ株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| KR101844184B1 (ko) * | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
| WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| WO2019245448A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Crystal modifications of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2020161217A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| JP7504110B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262277B1 (en) * | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| SE9901387D0 (sv) * | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) * | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| SE0003766D0 (sv) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
-
2002
- 2002-07-13 GB GBGB0216321.0A patent/GB0216321D0/en not_active Ceased
-
2003
- 2003-07-08 TW TW092118614A patent/TW200418821A/zh unknown
- 2003-07-09 AU AU2003246932A patent/AU2003246932A1/en not_active Abandoned
- 2003-07-09 JP JP2004520834A patent/JP2005536502A/ja active Pending
- 2003-07-09 PL PL03374665A patent/PL374665A1/xx not_active Application Discontinuation
- 2003-07-09 CN CNA038166941A patent/CN1668286A/zh active Pending
- 2003-07-09 CA CA002492374A patent/CA2492374A1/en not_active Abandoned
- 2003-07-09 MX MXPA05000461A patent/MXPA05000461A/es not_active Application Discontinuation
- 2003-07-09 BR BR0312427-4A patent/BR0312427A/pt not_active Application Discontinuation
- 2003-07-09 WO PCT/GB2003/002978 patent/WO2004006899A1/en not_active Application Discontinuation
- 2003-07-09 RU RU2004138083/15A patent/RU2004138083A/ru not_active Application Discontinuation
- 2003-07-09 US US10/520,939 patent/US20060083790A1/en not_active Abandoned
- 2003-07-09 EP EP03763979A patent/EP1539120A1/en not_active Withdrawn
- 2003-07-09 KR KR1020057000648A patent/KR20050027108A/ko not_active Application Discontinuation
- 2003-07-11 AR AR20030102516A patent/AR040553A1/es unknown
- 2003-07-11 UY UY27890A patent/UY27890A1/es not_active Application Discontinuation
-
2004
- 2004-12-17 NO NO20045527A patent/NO20045527L/no unknown
- 2004-12-30 IL IL16606804A patent/IL166068A0/xx unknown
-
2005
- 2005-01-10 ZA ZA200500212A patent/ZA200500212B/en unknown
- 2005-01-28 IS IS7678A patent/IS7678A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005536502A (ja) | 2005-12-02 |
| AR040553A1 (es) | 2005-04-13 |
| CA2492374A1 (en) | 2004-01-22 |
| IS7678A (is) | 2005-01-28 |
| AU2003246932A1 (en) | 2004-02-02 |
| TW200418821A (en) | 2004-10-01 |
| UY27890A1 (es) | 2004-02-27 |
| BR0312427A (pt) | 2005-04-19 |
| NO20045527L (no) | 2005-04-07 |
| GB0216321D0 (en) | 2002-08-21 |
| RU2004138083A (ru) | 2005-10-10 |
| KR20050027108A (ko) | 2005-03-17 |
| US20060083790A1 (en) | 2006-04-20 |
| WO2004006899A1 (en) | 2004-01-22 |
| MXPA05000461A (es) | 2005-03-23 |
| EP1539120A1 (en) | 2005-06-15 |
| PL374665A1 (en) | 2005-10-31 |
| ZA200500212B (en) | 2006-07-26 |
| CN1668286A (zh) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL166068A0 (en) | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | |
| EG25482A (en) | Inhibitors | |
| ZA200507996B (en) | Use of an IBAT inhibitor for the treatment or prophylaxis of constipation | |
| PL374846A1 (en) | New compounds for the inhibition of rotamases and use thereof | |
| HK1139681A1 (en) | Salts of valsartan | |
| HK1077762A1 (zh) | TFGß[轉化生長因子]的抑制劑 | |
| HK1080911A1 (en) | Rust inhibitor | |
| AU2003233426A8 (en) | Corrosion inhibitor | |
| IL165475A0 (en) | Nitrooxyderivatives of eyclooxygenase-2 inhibitors | |
| AU2003230392A8 (en) | Beta-secretase inhibitors | |
| GB0216154D0 (en) | Metal chelates | |
| AU2003242559A8 (en) | Alkylaminosiloxanes as corrosion inhibitors | |
| AU2003303949A8 (en) | Treatments for leishmaniasis | |
| AU2003294913A8 (en) | Hydrophobic-hydrophilic compounds for treating metallic surfaces | |
| GB0226101D0 (en) | White rust corrosion inhibitors | |
| GB0202187D0 (en) | "Inhibitors" | |
| GB2392919B (en) | Corrosion resistant steels | |
| AU2003239494A1 (en) | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | |
| AU2003216979A8 (en) | Corrosion testing of metals | |
| GB0226187D0 (en) | Corrosion inhibitor | |
| AU2003283454A1 (en) | Method and arrangement for treating the inner surface of a copper or copper alloy pipe | |
| AU2003231494A1 (en) | Body fat percentage-lowering agent or body fat percentage increase inhibitor | |
| GB0100485D0 (en) | Corrosion inhibitors | |
| GB0325222D0 (en) | Corrosion inhibitor | |
| GB0102192D0 (en) | Corrosion reduction |